

Received
8/27/02 *[Signature]* 008

AMENDMENT TRANSMITTAL LETTER (Small Entity)				Docket No. RTS-0333	
Applicant(s): Bennett and Dobie					
Serial No. 10/008,789	Filing Date November 8, 2001	Examiner Terra Gibbs		Group Art Unit 1645	
Invention: ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 6 EXPRESSION					
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
<input checked="" type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted. <input type="checkbox"/> A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	19 -	20 =	0 x	\$9.00	\$0.00
INDEP. CLAIMS	2 -	3 =	0 x	\$42.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed. <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
<i>[Signature]</i> _____ Signature				Dated: August 27, 2002	
Jane Massey Licata Reg. No. 32,257 Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454				I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.9 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. _____ Signature of Person Mailing Correspondence _____ Typed or Printed Name of Person Mailing Correspondence	
CC:					

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			Docket No.
Applicant(s): Bennett and Dobie			RTS-0333
Serial No. 10/008,789	Filing Date November 8, 2001	Examiner Terra Gibbs	Group Art Unit 1645
Invention: ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR 6 EXPRESSION			
<p>I hereby certify that this <u>Preliminary Amendment</u> (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-746-8693</u>) on <u>August 27, 2002</u> (Date)</p> <p><u>Jane Massey Licata</u> (Typed or Printed Name of Person Signing Certificate)</p> <p><u>Jane Massey Licata</u> (Signature)</p> <p>Note: Each paper must have its own certificate of mailing.</p>			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*Received Sun 8/27/02
Right Fax*

Attorney Docket No.: RTS-0333
Inventors: Bennett and Dobie
Serial No.: 10/008,789
Filing Date: November 8, 2001
Examiner: Terra Gibbs
Group Art Unit: 1614
Title: Antisense Modulation of Thyroid Hormone
Receptor Interactor 6 Expression

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile
transmitted to the Patent and Trademark Office on
the date shown below.

On August 27, 2002

Jane Massey Licata
Jane Massey Licata Registration No. 32,257

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

Claims 1-20 are pending in this application. Claim 1 is being
amended and claim 3 canceled to facilitate the search and
examination of this invention.

In the Claims:

Please cancel claim 3.

Please amend the claim 1 as follows:

1. (Amended) A compound 8 to 50 nucleobases in length targeted
to a nucleic acid molecule encoding thyroid hormone receptor